Achieving sustained virologic response in hepatitis C: A systematic review of the clinical, economic and quality of life benefits

BMC Infectious Diseases

Volumn 15, Issue 1, 2015, Pages 1-19

  Smith Palmer, Jayne ^a   Cerri, Karin ^b   Valentine, William ^a  

^a Ossian Health Economics and Communications GmbH   (Switzerland)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Chronic hepatitis c; Cost; Morbidity; Mortality; Quality of life; Sustained virologic response; Utility

Indexed keywords

ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BOCEPREVIR PLUS TELAPREVIR; PEGINTERFERON PLUS RIBAVIRIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER RISK; CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; DRUG TREATMENT FAILURE; ESOPHAGUS VARICES; HEALTH CARE COST; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MORTALITY; PORTAL HYPERTENSION; QUALITY OF LIFE; RELAPSE; REMISSION; RISK REDUCTION; SUSTAINED VIROLOGIC RESPONSE; SYSTEMATIC REVIEW; VIRAL CLEARANCE; VIRAL PHENOMENA AND FUNCTIONS; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH; HEPATITIS C, CHRONIC; PSYCHOLOGY; VIROLOGY;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; GLOBAL HEALTH; HEALTH CARE COSTS; HEPATITIS C, CHRONIC; HUMANS; QUALITY OF LIFE;

EID: 84923932929     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-015-0748-8     Document Type: Article

References (112)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333-42.
2. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118:3030-44.
3. Jacobson IM, Poordad F, Brown Jr RS, Kwo PY, Reddy KR, Schiff E. Standardization of terminology of virological response in the treatment of chronic hepatitis C: panel recommendations. J Viral Hepat. 2012;19:236-43.
4. Wedemeyer H, Jensen DM, Godofsky E, Mani N, Pawlotsky JM, Miller V, et al. Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents. Hepatology. 2012;56:2398-403.
5. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;S0140-6736(14):60494-3.
6. Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014;S0140-6736(14):60538-9.
7. Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naïve patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013;381:2100-7.
8. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878-87.
9. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889-98.
10. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483-93.
11. Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis. 2011;52:889-900.
12. Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology. 2010;139:1593-601.
13. Martinot-Peignoux M, Stern C, Maylin S, Ripault MP, Boyer N, Leclere L, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology. 2010;51:1122-6.
14. Campos-Varela I, Castells L, Esteban JI, Bes M, Rodríguez-Frías F, Sapisochin G, et al. Twelve-week posttreatment follow-up to predict sustained virologic response for recurrent hepatitis C infection in liver recipients. Transplantation. 2012;93:450-3.
15. Chen J, Florian J, Carter W, Fleischer RD, Hammerstrom TS, Jadhav PR, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology. 2013;144:1450-5.
16. El Khoury AC, Wallace C, Klimack WK, Razavi H. Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas. J Med Econ. 2012;15:887-96.
17. Mauss S, Petersen J, Witthoeft T, Busch HW, Christensen S, Zehnter E, et al. Sustained Responders have Lower Rates of Liver-Related Events and a Better Quality of Life and Productivity Compared with Non-Responders/Relapsers after Antiviral Treatment of Chronic Hepatitis C [abstract] Hepatology. 63rd Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2012 Boston, MA United States. 9-13 November 2012 pp 5
18. John-Baptiste AA, Tomlinson G, Hsu PC, Krajden M, Heathcote EJ, Laporte A, et al. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol. 2009;104:2439-48.
19. Deuffic-Burban S, Mathurin P, Pol S, Larsen C, Roudot-Thoraval F, Desenclos JC, et al. Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis. Gut. 2012;61:290-6.
20. Van Der Meer AJP, Veldt BJ, Feld JJ, Wedemeyer H, Dufour J-F, Lammert F, et al. Improvement of interferon-based therapy substantially reduced the number needed to treat to prevent HCC among HCV genotype 1 infected cirrhotics [abstract]. Amsterdam, Netherlands: 48th Annual Meeting of the European Association for the Study of the Liver; 2013.
21. Wang C-H, Chang K-K, Lin R-C, Kuo J-J. Insights into hepatocellular carcinoma occurrence and long-term outcomes in patients with chronic hepatitis C infection after successful antiviral treatment [abstract]. Singapore: 23rd Conference of the Asian Pacific Association for the Study of the Liver; 2013.
22. Sasaki R, Abiru S, Yamasaki K, Komori A, Yatsuhashi H. Risk factors for hepatocellular carcinoma developed after sustained virological response in hepatitis C patients [abstract]. Brisbane, Australia: Abstract presented at the 23rd Conference of the Asian Pacific Association for the Study of the Liver; 2014.
23. Calvaruso V, Bavetta MG, Ferraro D, Grimaudo S, Conte E, Pipitone RM, et al. Risk of disease decompensation and HCC in patients with HCV cirrhosis non responders to PEG IFN plus RBV [abstract]. Bologna, Italy: 19th National Congress of Digestive Diseases, Italian Federation of Societies of Digestive Diseases; 2013.
24. Hara T, Fukushima T, Kawamura Y, Sezaki H, Hosaka T, Akuta N, et al.Sustained viral response reduces liver complications and total mortality among Japanese elderly with hepatitis C virus infection [abstract]. Brisbane, Australia: 23rd Conference of the Asian Pacific Association for the Study of the Liver; 2014.
25. Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Maruyama T, et al. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. J Hepatol. 2013;58:495-501.
26. Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N, et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis. 2013;57:230-6.
27. Pellicelli AM, Vignally P, Romano M, Miglioresi L, Mazzoni E, Mecenate F, et al. Impact of liver fibrosis in development of hepatocellular carcinoma in genotype 1 chronic hepatitis C patients treated with antiviral therapy: Long term follow up study [abstract]. 48th Annual Meeting of the European Association for the Study of the Liver, International Liver Congress 2013 Amsterdam Netherlands. 24-28 April 2013
28. Imai Y, Tamura S, Tanaka H, Hiramatsu N, Kiso S, Doi Y, et al. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders. J Viral Hepat. 2010;17:185-91.
29. Kobayashi S, Takeda T, Enomoto M, Tamori A, Kawada N, Habu D, et al. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. Liver Int. 2007;27:186-91.
30. Hung CH, Lee CM, Lu SN, Wang JH, Hu TH, Tung HD, et al. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat. 2006;13:409-14.
31. Moriyama M, Matsumura H, Aoki H, Shimizu T, Yamagami H, Shioda A, et al. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy. Liver Int. 2005;25:85-90.
32. Watanabe S, Enomoto N, Koike K, Izumi N, Takikawa H, Hashimoto E, et al. Cancer preventive effect of pegylated interferon α-2b plus ribavirin in a real-life clinical setting in Japan: PERFECT interim analysis. Hepatol Res. 2011;41:955-64.
33. Wang CH, Mo LR, Chang KK, Lin RC, Kuo JJ. A cohort study to investigate hepatocellular carcinoma risk in hepatitis C patients. Hepatogastroenterology. 2011;58:904-8.
34. Sasaki M, Yoshida K, Yoshimatsu S, Setoyama H, Chiyonaga S, Narita R, et al. Hepatocarcinogenesis after SVR by interferon therapy in chronic hepatitis C patients [abstract]. Journal of Gastroenterology and Hepatology. Asian Pacific Digestive Week 2011 Singapore. 1-4 October 2011 pp 169
35. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Someya T, Hosaka T, et al. Anticarcinogenic impact of interferon on patients with chronic hepatitis C: a large-scale long-term study in a single center. Intervirology. 2006;49:82-90.
36. Yoshida H, Tateishi R, Arakawa Y, Sata M, Fujiyama S, Nishiguchi S, et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut. 2004;53:425-30.
37. Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, et al. Complete Hepatitis C virus elimination during pegylated interferon a2B and ribavirin treatment reduces the risk of progression to hepatocellular carcinoma [abstract]. Journal of Hepatology. 47th Annual Meeting of the European Association for the Study of the Liver, International Liver Congress 2012 Barcelona Spain. 18-22 April 2012
38. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584-93.
39. Velosa J, Serejo F, Marinho R, Nunes J, Glória H. Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis. Dig Dis Sci. 2011;56:1853-61.
40. Maruoka D, Imazeki F, Arai M, Kanda T, Fujiwara K, Yokosuka O. Long-term cohort study of chronic hepatitis C according to interferon efficacy. J Gastroenterol Hepatol. 2012;27:291-9.
41. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52:833-44.
42. Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol. 2010;52:652-7.
43. Braks RE, Ganne-Carrie N, Fontaine H, Paries J, Grando-Lemaire V, Beaugrand M, et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol. 2007;13:5648-53.
44. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579-87.
45. Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, Lu SN, et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther. 2006;11:985-94.
46. Imazeki F, Yokosuka O, Fukai K, Kawai S, Kanda T, Kojima H, et al. Lower incidence of hepatic failure than hepatocellular carcinoma in Japanese patients with chronic hepatitis C. Liver Int. 2005;25:772-8.
47. Coverdale SA, Khan MH, Byth K, Lin R, Weltman M, George J, et al. Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study. Am J Gastroenterol. 2004;99:636-44.
48. Shih K, Su W-W, Hsu Y-C, Yen H-H, Wu S-S, Soon M-S Interferon-based treatment reduced hepatocellular carcinoma development and liver related death incidence in chronic hepatitis C patients V Single institution experience [abstract]. Hepatology International. 22nd Conference of the Asian Pacific Association for the Study of the Liver, APASL 2012 Taipei Taiwan (Republic of China). 16-19 February 2012
49. Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol. 2010;8:192-9.
50. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8:280-8.
51. Kimer N, Dahl EK, Gluud LL, Krag A. Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2012;2(5):1-7.
52. Ng V, Saab S. Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2011;9:923-30.
53. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158:329-37.
54. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41-52.
55. Namiki I, Nishiguchi S, Hino K, Suzuki F, Kumada H, Itoh Y, et al. Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res. 2010;40:347-68.
56. Innes HA, Hutchinson SJ, Allen S, Bhattacharyya D, Bramley P, Delahooke TE, et al. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. Hepatology. 2011;54:1547-58.
57. Kasahara A, Tanaka H, Okanoue T, Imai Y, Tsubouchi H, Yoshioka K, et al. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J Viral Hepat. 2004;11:148-56.
58. Imazeki F, Yokosuka O, Fukai K, Saisho H. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology. 2003;38:493-502.
59. Selzner N, Renner EL, Selzner M, Adeyi O, Kashfi A, Therapondos G, et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation. 2009;88:1214-21.
60. Tanaka T, Selzner N, Therapondos G, Renner EL, Lilly LB. Virological response for recurrent hepatitis C improves long-term survival in liver transplant recipients. Transpl Int. 2013;26:42-9.
61. Van Der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour J-F, Lammert F, et al. Sustained virological response improves overall survival in chronic hepatitis C patients with advanced fibrosis [abstract]. Hepatology. 63rd Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2012 Boston, MA United States. 9-13 November 2012
62. Aguilera V, Garcia M, Rubin A, Navarro L, Prieto M, Berenguer M. Improved outcome after anti-hcv therapy is less marked when therapy is started at advanced stages of fibrosis [abstract]. Journal of Hepatology. 47th Annual Meeting of the European Association for the Study of the Liver, International Liver Congress 2012 Barcelona Spain. 18-22 April 2012
63. Kutala BK, Duval X, Guedj J, Asselah T, Marcellin P. Impact of antiviral therapy on survival in patients with advanced fibrosis - Experience of Beaujon Hospital 2000 to 2010 [abstract]. Amsterdam, Netherlands: 48th Annual Meeting of the European Association for the Study of the Liver; 2013.
64. Uenishi T, Nishiguchi S, Tanaka S, Yamamoto T, Takemura S, Kubo S. Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. J Surg Oncol. 2008;98:358-62.
65. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9:509-16.
66. Cozen ML, Ryan JC, Shen H, Lerrigo R, Yee RM, Sheen E, et al. Nonresponse to interferon-α based treatment for chronic hepatitis C infection is associated with increased hazard of cirrhosis. PLoS One. 2013;8:e61568.
67. Dieperink E, Pocha C, Thuras P, Knott A, Colton S, Ho SB. All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C. Dig Dis Sci. 2014;59:872-80.
68. Singal AG, Dharia TD, Malet PF, Alqahtani S, Zhang S, Cuthbert JA. Long-term benefit of hepatitis C therapy in a safety net hospital system: a cross-sectional study with median 5-year follow-up. BMJ Open. 2013;3(9):e003231.
69. Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology. 2009;49:739-44.
70. Simó R, Lecube A, Genescà J, Esteban JI, Hernández C. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care. 2006;29:2462-6.
71. Oni OA, Rao G, Pandya PK. Impact of sustained virologic response on incident diabetes in chronic hepatitis C [abstract] Hepatology. 62nd Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2011 San Francisco, CA United States. 4-8 November 2011
72. Hyder SM, Krishnan S, Promrat K. Sustained virological response prevents the development of new type 2 diabetes in patients with chronic hepatitis C [abstract]. Gastroenterology. 2013;144(5 Suppl 1):S951. Conference: Digestive Disease Week 2013, DDW 2013 Orlando, FL United States. 18-21 May 2013.
73. Abergel A, Darcha C, Chevallier M, Ughetto S, Henquell C, Pol S, et al. Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis. Eur J Gastroenterol Hepatol. 2004;16:1219-27.
74. Poynard T, Moussalli J, Munteanu M, Thabut D, Lebray P, Rudler M, et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol. 2013;59:675-83.
75. Roche B, Sebagh M, Canfora ML, Antonini T, Roque-Afonso AM, Delvart V, et al. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl. 2008;14:1766-77.
76. Wiese M, Fischer J, Löbermann M, Göbel U, Grüngreiff K, Güthoff W, et al. Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. Hepatology. 2014;59:49-57.
77. Annicchiarico BE, Siciliano M, Santonocito C, Zocco MA, Avolio AW, Barbaro F. Long-term outcome of hepatitis C-related liver cirrhosis at different stages of portal hypertension after sustained virological response [abstract] Hepatology. 63rd Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2012 Boston, MA United States. 9-13 November 2012
78. Bruno S, Crosignani A, Facciotto C, Rossi S, Roffi L, Redaelli A, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology. 2010;51:2069-76.
79. D'Ambrosio R, Aghemo A, Rumi MG, Primignani M, Dell'Era A, Lampertico P, et al. The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy. Antivir Ther. 2011;16:677-84.
80. Lee SJ, Yeon JE, Lee HJ, Yoon EL, Suh SJ, Kim JH, et al. Risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis C; long term outcome and prognostic factors [abstract]. Singapore: 23rd conference of the Asian Pacific Association for the Study of the Liver; 2013.
81. Canete N, Garcia M, Ojanguren I, Cirera I, Garcia-Retortillo M, Carrion JA, et al. Long-term evolution of liver fibrosis in mild-moderate chronic hepatitis C: Study with paired biopsies [abstract]. Journal of Hepatology. 48th Annual Meeting of the European Association for the Study of the Liver, International Liver Congress 2013 Amsterdam Netherlands. 18-24 April 2013
82. Basseri B, Yamini D, Chee G, Enayati PD, Tran T, Poordad F. Comorbidities associated with the increasing burden of hepatitis C infection. Liver Int. 2010;30:1012-8.
83. McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm. 2011;17:531-46.
84. Vietri J, Prajapati G, El Khoury AC. The burden of hepatitis C in Europe from the patients' perspective: a survey in 5 countries. BMC Gastroenterol. 2013;13:16.
85. Backx M, Lewszuk A, White JR, Cole J, Sreedharan A, van Sanden S, et al. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy. J Viral Hepat. 2014;21:208-15.
86. Morais AD, Pereira ML. Cost per cure of telaprevir and boceprevir in treatment-naive genotype 1 hepatitis c patients with F2 fibrosis in Brazil [abstract]. Dublin, Ireland: ISPOR 16th Annual European Congress; 2013.
87. Cammà C, Petta S, Enea M, Bruno R, Bronte F, Capursi V, et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology. 2012;56:850-60.
88. Yfantopoulos J, Paparouni K, D'Angelo ER. A cost-effectiveness analysis of telaprevir versus boceprevir in the treatment of hepatitis C: A greek national health system perspective [abstract]. Berlin Germany: ISPOR 15th Annual European Congress; 2012. p. A394.
89. Manos MM, Darbinian J, Rubin J, Ray GT, Shvachko V, Denis B, et al. The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting. J Manag Care Pharm. 2013;19:438-47.
90. Bini EJ, Mehandru S. Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels. Aliment Pharmacol Ther. 2006;23:777-85.
91. Arora S, O'Brien C, Zeuzem S, Shiffman ML, Diago M, Tran A, et al. Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon α-2a (40 kDa) plus ribavirin: impact on health-related quality of life. J Gastroenterol Hepatol. 2006;21:406-12.
92. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005;41:790-800.
93. Thein HH, Krahn M, Kaldor JM, Dore GJ. Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol. 2005;100:643-51.
94. Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai MY, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol. 2004;40:675-81.
95. Chong CA, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol. 2003;98:630-8.
96. Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Sterling RK, et al. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol. 2007;46:420-31.
97. Mathew A, Peiffer LP, Rhoades K, McGarrity TJ. Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with Pegylated interferon alpha -2b and ribavirin. Health Qual Life Outcomes. 2006;4:30.
98. Hollander A, Foster GR, Weiland O. Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C. Scand J Gastroenterol. 2006;41:577-85.
99. Van Rooijen EM, Hotho D, Agthoven M, Van Der Kolk A, Hansen BE, Knegt R, Uyl-De Groot CA. The cost and quality of life of hepatitis C in the Netherlands [abstract]. Value in Health. ISPOR 14th Annual European Congress Madrid Spain. 5-8 November 2011. pp A394
100. Papastergiou V, Skorda L, Lisgos P, Hletsos M, Ketikoglou I, Zamanis C, Karatapanis S. Health-related quality of life in patients with chronic hepatitis C. The impact of antiviral therapy. European Journal of Internal Medicine. 10th Congress of the European Federation of Internal Medicine Athens Greece. 5-8 November 2011 pp S46
101. Björnsson E, Verbaan H, Oksanen A, Frydén A, Johansson J, Friberg S, et al. Health-related quality of life in patients with different stages of liver disease induced by hepatitis C. Scand J Gastroenterol. 2009;44:878-87.
102. Younossi Z, Aggarwal J, Martin M, Hernandez N, Donepudi M, Bayliss M, et al. Health-related quality-of-life among genotype 1 treatment-naive chronic Hepatitis C patients receiving telaprevir combination treatment: Post-hoc analyses of data from the advance trial [abstract]. Journal of Hepatology. 47th Annual Meeting of the European Association for the Study of the Liver, International Liver Congress 2012 Barcelona Spain. 18-22 April 2012
103. Hsu PC, Federico CA, Krajden M, Yoshida EM, Bremner KE, Anderson FH, et al. Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. J Gastroenterol Hepatol. 2012;27:149-57.
104. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med. 2012;156:279-90.
105. Chhatwal J, Ferrante SA, Brass C, El Khoury AC, Burroughs M, Bacon B, et al. Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value Health. 2013;16:973-86.
106. Veldt BJ, Saracco G, Boyer N, Cammà C, Bellobuono A, Hopf U, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut. 2004;53:1504-8.
107. Almasio PL, Venezia G, Craxì A. The impact of antiviral therapy on the course of chronic HCV infection. A systematic review. Panminerva Med. 2003;45:175-82.
108. Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol. 2009;50:1142-54.
109. Tanaka Y, Hanada K, Orito E, Akahane Y, Chayama K, Yoshizawa H, et al. Molecular evolutionary analyses implicate injection treatment for schistosomiasis in the initial hepatitis C epidemics in Japan. J Hepatol. 2005;42:47-53.
110. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med. 2000;133(8):592-9.
111. Romero-Gómez M, Del Mar VM, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128:636-41.
112. Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med. 2005;142:105-14.